Benza, Raymond L.
Franco, Veronica
Aras, Mandar A.
Spikes, Leslie
Grinnan, Daniel
Satler, Carol
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety and efficacy of RT234 vardenafil inhalation powder on exercise parameters in pulmonary arterial hypertension: phase II, dose-escalation study design
https://doi.org/10.1186/s12931-022-02262-9
Funding for this research was provided by:
Respira Therapeutics Inc
Article History
Received: 19 August 2022
Accepted: 27 November 2022
First Online: 17 December 2022
Declarations
:
: The trial will be conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice Guidelines of the International Conference on Harmonisation, along with all local regulatory requirements. The informed consent document and the protocol have been or will be reviewed and approved by each investigator’s designated Institutional Review Board/Independent Ethics Committee and by the sponsor. The trial is registered at ClinicalTrials.gov (identifier NCT04266197).
: Not applicable.
: RLB is on the steering committee for Abbott Laboratories, Cereno Scientific, Gossamer Bio, Respira Therapeutics, and United Therapeutics. VF is employed by The Ohio State University, which receives research support from Abbott Laboratories, Acceleron Pharma, Endotronix, Respira Therapeutics, and United Therapeutics. MAA has no interests to declare. LS is the principal investigator for trials sponsored by Acceleron Pharma, Bayer, Gossamer Bio, Insmed, Merck, Respira Therapeutics, and United Therapeutics. DG received grant support from and is on the grant review committee at Bayer and received grant support from Respira Therapeutics. CS is a current employee of Respira Therapeutics.